Balanced breakfasts improve heart and metabolic health in older adults
December 16, 2024 / Cardiometabolic Health / Obesity / HDL Cholesterol and Triglycerides / Meditterranean Diet / Metabolic Syndrome
A balanced, nutrient-rich breakfast comprising 20–30% of daily energy intake improves cardiometabolic health in older adults, lowering triglycerides, increasing HDL cholesterol, and enhancing kidney function, while extremes in breakfast energy intake worsen adiposity and lipid profiles.
Exploring the heterogeneity of metabolic dysfunction-associated steatotic liver disease
December 16, 2024 / Metabolic Dysfunction-associated Steatotic Liver Disease / MASLD Pathogenesis and Treatment / MASLD Obesity and Diabetes Link
Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits significant heterogeneity in pathogenesis and treatment response, driven by genetic and metabolic factors. Precision medicine approaches may enable personalized therapies targeting obesity, diabetes, and cardiovascular risk linked to MASLD.
Novel GLP-1 analog injection reduced weight for Chinese adults with overweight, obesity
December 16, 2024 / GLP-1 Analog Weight Loss / Obesity Treatment / Overweight Obesity / Cardiometabolic Improvements GLP-1
GLP-1 analog injections (GZR18) safely reduced body weight and improved cardiometabolic parameters in Chinese adults with overweight or obesity. Weekly and biweekly doses achieved up to 16.8% weight loss over 30 weeks, showing robust efficacy and tolerability.
Targeting a Brain Enzyme May Be the Key to Unlocking New Obesity Strategies
December 16, 2024 / Brain Enzyme ABHD6 Obesity / Weight Control / Obesity Research / Targeted Brain Therapies Obesity
Targeting the brain enzyme ABHD6 in the nucleus accumbens reduces weight gain, increases physical activity, and decreases food motivation in mice. ABHD6 inhibition may offer a novel strategy for obesity and metabolic disorder therapies without adverse mood effects.
Revolutionizing MASLD treatment with GLP-1 receptor agonists
December 16, 2024 / GLP-1 Receptor Agonists MASLD / MASH Treatment / Liver Fibrosis Improvement / Smaglutide and Tirzepatide MASLD
GLP-1 receptor agonists (GLP-1RAs) show promise in treating MASLD by reducing hepatic steatosis, improving MASH resolution, and mitigating fibrosis progression. Agents like liraglutide, semaglutide, and tirzepatide target metabolic dysfunction, offering new therapeutic options alongside lifestyle interventions.
Mitochondrial dysfunction has a central role in diabetic kidney disease
December 16, 2024 / Mitochondrial Dysfunction Diabetic Kidney Disease / Fatty Acid Oxidation DKD / Urinary Lactate Kidney Function / Mitochondrial Biomarkers
Mitochondrial dysfunction, including defects in fatty acid oxidation, disrupted oxidative metabolism, and respiratory supercomplex instability, drives diabetic kidney disease (DKD) progression. Biomarkers like urinary lactate highlight mitochondrial abnormalities as key contributors to DKD development and kidney function decline.
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
December 16, 2024 / Relacorilant Hypercortisolism Treatment / Cardiometabolic Improvements / Cushing’s Syndrome / Cortisol Modulation Relacorilant Efficacy
Relacorilant demonstrated durable improvements in blood pressure, glycemic control, and cardiometabolic health in patients with hypercortisolism over six years. The Phase 3 long-term study confirms relacorilant’s safety, efficacy, and potential as a new standard of care.
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
December 16, 2024 / PKU GOLIKE Clinical Trial Results / Phenylketonuria Metabolic Control / Amino Acid Substitutes
PKU GOLIKE demonstrated significant metabolic control improvements in phenylketonuria (PKU) patients during overnight fasting, reducing blood phenylalanine and increasing tyrosine levels. Its prolonged-release profile outperformed standard amino acid substitutes, supporting its clinical use for managing PKU.
Zepbound Helps People Lose More Weight Than Wegovy, According to Eli Lilly Trial
December 14, 2024 / Zepbound vs Wegovy Weight Loss / Tirzepatide Dual Hormone Action / GLP-1 and GIP Obesity Treatment / Weight Loss
Eli Lilly’s Zepbound demonstrated superior weight loss (20.2%) compared to Novo Nordisk’s Wegovy (13.7%) in a head-to-head trial. Tirzepatide’s dual action on GLP-1 and GIP may drive its enhanced efficacy, with mild-to-moderate gastrointestinal side effects reported.
Scientists lay out new framework to identify toxics contributing to metabolic disorders
December 13, 2024 / Metabolic-disrupting Agents Framework / Environmental Chemicals and Obesity / Diabetes Risk Toxic Chemicals / Metabolic Disruption
A new framework outlines 12 key characteristics to identify metabolic-disrupting agents, including chemicals and environmental hazards that impair metabolic pathways, contributing to obesity and diabetes. This approach aims to improve testing, risk assessment, and prevention strategies for metabolic disorders.
Hepatocellular Carcinoma Mortality Rates Rising in the US, Driven by Alcohol and Metabolic Liver Diseases
December 13, 2024 / HCC Mortality Alchol Liver Disease / MASLD / Hepatocellular Carcinoma / Liver Cancer Disparities
Hepatocellular carcinoma (HCC) mortality rates in the U.S. are rising, driven by alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD). Significant age, racial, and gender disparities necessitate targeted prevention, screening, and public health interventions.
Moderate Alcohol Consumption Fuels Liver Disease Progression in People With MASLD
December 13, 2024 /
Alcohol Consumption / MASLD Progression / Liver Fibrosis / Metabolic Risk / Liver Disease
Moderate alcohol consumption significantly accelerates liver fibrosis progression in individuals with MASLD, with no safe alcohol threshold identified. A dose-dependent relationship between metabolic risk factors and alcohol intake highlights its compounding impact on liver disease progression, including advanced fibrosis and MASH risk.
PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment
December 12, 2024 / Myostatin Inhibitors Lean Mass / Semaglutide Combination Therapy / Weight Loss Muscle Preservation / Oral Myostatin Inhibitors / PeptiDream
PeptiDream’s preclinical results demonstrate that oral myostatin inhibitors, combined with semaglutide, effectively promote weight loss while preserving lean body mass in obesity models. This novel combination therapy could address muscle loss, a limitation of current weight-loss treatments.
Decreased Adipose Lipid Turnover Associates With Cardiometabolic Risk and the Metabolic Syndrome
December 12, 2024 / Adipose Lipid Turnover Metabolic Syndrome / Lipid Mobilization Cardiometabolic Risk / White Adipose Tissue Lipid Age
Decreased adipose lipid turnover, particularly impaired lipolysis, is linked to cardiometabolic risk and metabolic syndrome. Despite normal lipid storage capacity, lipid age increases in metabolic syndrome, highlighting disrupted fat mobilization as a key contributor to cardiometabolic dysfunction.
Researchers describe a potential target to address a severe heart disease in diabetic patients
December 12, 2024 / PPARβ/δ diabetic cardiomyopathy treatment / Inflammation Fibrosis Heart Failure / Diabetes / Cardiac Metabolism / Diabetic Heart Disease Therapeutic Target
PPARβ/δ activation reduces inflammation, fibrosis, and apoptosis in diabetic cardiomyopathy by inhibiting the MAPK pathway. This approach improves cardiac metabolism and function, offering a promising therapeutic target to mitigate heart disease progression in diabetic patients.
Early weight loss with tirzepatide predictive of larger cardiometabolic benefits later on
December 11, 2024 / Tirzepatide Early Weight Loss / Cardiometabolic Benefits Trizepatide / Weight Loss Results / Predicting Obesity Treatment Success
Early weight loss (≥5% at 8 weeks) with tirzepatide predicts greater long-term weight reduction and cardiometabolic benefits, including improved HbA1c, blood pressure, and triglycerides. These findings emphasize early response as a key indicator for treatment success.
Shivering for 1 hour a day may boost glucose tolerance and metabolic health
December 10, 2024 / Cold Exposure Glucose Tolerance / Metabolic Health / Insulin Sensitivity / Obeisty Glucose Control
Cold exposure inducing shivering for 1 hour daily over 10 days improved glucose tolerance, lowered fasting glucose, triglycerides, and blood pressure in adults with obesity. Shivering appears critical for enhancing insulin sensitivity and overall cardiometabolic health.